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Rationale.  There is a well-recognized need for a noninvasive tool allowing the detection of 
vulnerable atherosclerotic plaques. By combining nanomolar affinities and fast blood clearance, 
nanobodies represent potential generic radiotracers for cardiovascular molecular imaging. As an 
inflammatory marker, Vascular Cell Adhesion Molecule-1 (VCAM1) constitutes a relevant target for 
molecular imaging of atherosclerotic lesions.  
Objective. We aimed to generate, radiolabel and evaluate anti-VCAM1 nanobodies for noninvasive 
detection of atherosclerotic lesions.  
Methods and Results. Ten anti-mouse or anti-mouse/human VCAM1 crossreactive nanobodies with 
nanomolar affinities were generated, radiolabeled with technetium-99m and screened in vitro on 
mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in ApoE-deficient 
(ApoE
-/-
) mice. A nontargeting control nanobody was used in all experiments to demonstrate 
specificity. The lead compound, identified as nanobody cAbVCAM1-5, was found crossreactive for 
human VCAM1 and exhibited high lesion-to-control (4.95±0.85), lesion-to-heart (8.30±1.11), and 
lesion-to-blood ratios (4.32±0.48) (P<0.05 vs control C57Bl/6J mice for all 3 ratios). Atherosclerotic 
lesions located within the aortic arch of ApoE
-/-
 mice were successfully identified by SPECT/CT 
imaging. 
99m
Tc-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition 
experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in 
VCAM1-positive lesions.  
Conclusions. The 
99m
Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive 
detection of VCAM1 expression and displayed mouse and human crossreactivity. Therefore, this study 
demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. 
The nanobody technology might evolve into an important research tool for targeted imaging of 
atherosclerotic lesions and has the potential for fast clinical translation. 
 
Keywords: atherosclerosis, imaging, nanobody, nuclear medicine. 
 




mVCAM1/hVCAM1: mouse/human vascular cell adhesion molecule-1 
ICAM1: intercellular adhesion molecule-1 
VLA4: very late antigen-4 
kDa: kilodaltons 
EGFR: epidermal growth factor receptor 
CEA: carcinembryonic antigen 
HER2: human epidermal growth factor receptor 2 
99m
Tc: technetium-99m 
VH: variable domain from conventional antibodies 
VHH: variable domain from heavy-chain-only antibodies 
RT: reverse transcription 
PCR: polymerase chain reaction 
RNA: ribonucleic acid 
ELISA: enzyme-linked immunosorbent assay 
TNF: tumor necrosis factor alpha 
PE: phycoerythrin 
mAb: monoclonal antibody 
IgG: Immunoglobulin class G 
Tm: unfolding temperature 
SPR: surface plasmon resonance 
HUVEC: human umbillical vein endothelial cells 
PBS: phosphate-buffered saline 





TFA: Trifluoroacetic acid 
HSA: Human Serum Albumine 
i.v.: intravenous 
SPECT: Single Photon Emission Computed Tomography 
PET: positron emission tomography 
CT: (X-ray) Computed Tomography 
%ID/g: percent of injected dose per gram 
%ID/cm
3
: percent of injected dose per cubic centimeter 
%ID/TBV: percent of injected dose in total blood volume 
DAB: 3,3'-Diaminobenzidine 
ROI: region of interest 
s.e.m.: standard error of the mean 




LN: lymph nodes 
Tm: thymus 
Sp: spleen 
ao: aortic arch 
SM: skeletal muscle 
SG: salivary glands 
BM: bone marrow 
ARG: autoradiogram 




Several radiotracers of various chemical natures have been evaluated so far for nuclear imaging of 
atherosclerotic lesions, including lipoproteins, peptides, oligopeptides, antibodies, carbohydrates, 
antisense nucleotides and nanoparticles
1
. However, none of these radiotracers is currently used in 
routine clinical practice, mostly because of their inability to reach sufficient lesion-to-background 
ratios in vivo. Indeed, nuclear imaging of vulnerable plaques at the level of coronary arteries remains 
challenging, mostly because of the small volume of the lesions and their vicinity with the blood 
containing unbound circulating tracer. Thus, an ideal tracer should combine high affinity and 
specificity, good solubility and stability and efficient radiolabeling with small size and fast blood 
clearance, so that high contrast images can be obtained shortly after administration. Nanobodies 
constitute a promising new class of radiotracers that might adhere to these conditions. Nanobodies are 
derived from unique heavy-chain-only antibodies that are by nature present in camelids and represent 
the smallest possible (10-15 kDa) functional immunoglobulin-like antigen-binding fragment. 
Nanobody-based tracers targeting cancer antigens EGFR, CEA or HER2 with (sub)nanomolar 




The inflammatory process leading to the development of vulnerable atherosclerotic lesions is 
characterized by extensive recruitment of monocytes and lymphocytes into the arterial wall
6
. Several 
endothelial adhesion molecules are implicated in the process of leukocyte rolling, firm adhesion and 
transmigration, such as E- and P-selectins, vascular cell adhesion molecule-1 (VCAM1) and 
intercellular adhesion molecule-1 (ICAM1)
7
. VCAM1 is a receptor of the immunoglobulin family that 
binds to very late antigen-4 (VLA4) present on the surface of leukocytes
8
. As active inflammation 
characterized by leukocyte infiltration is recognized as a major criterion for defining a vulnerable 
plaque
9
, the adhesion molecule VCAM1 is a relevant molecular target for noninvasive detection of 
such lesions. Indeed, VCAM1 expression was observed at the level of the luminal endothelium as well 
as on neovessels of advanced lesions, on macrophages and on activated smooth muscle cells
10-12
 
Therefore, molecular probes targeting VCAM1 have been evaluated by our group and others either for 
nuclear, magnetic resonance, fluorescent or ultrasound in vivo imaging
13-16. 
In the present study, our objectives were to generate and evaluate nanobody-based radiolabeled tracers 
for preclinical imaging of atherosclerotic plaques. Specifically, we describe 1) the generation and full 
in vitro characterization of crossreactive mouse and human VCAM1-targeted nanobodies; 2) their 
99m
Tc-radiolabeling; and 3) their thorough assessment as tracers for noninvasive in vivo nuclear 




Material and Methods 
 
An exhaustive version of this section is available in the Supplemental data file.  
 
Nanobody generation and production 
VCAM1-targeting nanobodies were generated largely following published methods
17
. Specifically, a 
dromedary was immunized with both mouse and human recombinant VCAM1 proteins (RnD 
Systems), blood lymphocytes were isolated and RNA purified. The variable domains of the heavy-
chain-only antibodies (VHHs or nanobodies) were amplified using a two-step RT-PCR method and 
cloned in frame with M13 bacteriophage gene 3. Nanobodies were phage-displayed and used in 
biopannings on immobilized immunogens. Crude bacterial extracts containing soluble nanobodies 
were used to select individual VCAM1 binders based on a positive signal in ELISA and in flow 
cytometry on TNFα-stimulated bEND5 cells. After sequencing, selected anti-VCAM1 and irrelevant 





In vitro evaluation of unlabeled nanobodies 
Cell lines - The mouse endothelial cell line bEND5 (ECACC) was cultured in supplemented DMEM 
medium, and the human umbilical vein endothelial cells HUVEC in supplemented EndoGro basal 
medium (Millipore).  VCAM1 expression was induced by stimulation with 10 ng/mL TNFα during 
 5 
18h. 
Flow cytometry –105 TNFα-stimulated and unstimulated cells were incubated either with PE-labeled 
anti-VCAM1 monoclonal antibody (mAb) (anti-mouse from Abcam; anti-human from RnD Systems), 
or sequentially with 1µg nanobody, 1µg anti-His-tag mAb (Serotec) and 200ng PE-labeled rat anti-
mouse IgG1 (BD Biosciences). Binding was measured on a FACS Canto II analyzer (BD Biosciences) 
and data analyzed with FlowJo software (TreeStar). 
Thermal stability – Tm values (unfolding temperatures) were obtained on a J-715 spectropolarimeter 
(Jasco, Easton, MD, USA), as previously described
4
. 
Surface Plasmon Resonance (SPR)-based affinity evaluation – Nanobodies affinity for recombinant 
human and mouse VCAM1 was determined by SPR analysis on a Biacore 3000 apparatus. 
Recombinant mouse ICAM1 (RnD Systems) was used as a negative control. Recombinant proteins 
were immobilized on a CM5 sensor chip (Biacore) according to the manufacturer’s instructions. A 2-
fold dilution series of nanobodies from 50 to 1 nmol/L were tested. Affinity constants were determined 
using a 1:1 standard association model fit (BIAevaluation software). 
Epitope competition using SPR - SPR was used to determine which nanobodies compete for the same 




Radiolabeling and HPLC assessment of in vitro and in vivo stability 




tricarbonyl-method, as described elsewhere
3
. 
Radiochemical purity was assessed immediately after labeling, after 6h at 20°C in PBS and in mouse 
blood 3h post-injection (p.i.). In the latter case, 100µL sampled whole blood was centrifuged and 
plasma was filtered using a Nanosep 10 kDa Omega Membrane. Radiochemical purity was determined 
by RP-HPLC using a C4 column eluted with an ACN/TFA gradient mobile phase. Radioactivity was 
monitored using a radiodetector (γ-RAM Model 4, LabLogic). 
 





 bEND5 cells were plated in 24-well plates and stimulated 18h with 10ng/ml TNFα. Five 
nmol/L of each 
99m
Tc-nanobody was incubated in 0.5mL PBS + 1% HSA for 1.5h at 37ºC. 
Competition studies with a 500-fold excess of unlabeled nanobody were conducted to assess the 
specificity of the binding. After washing, bound 
99m
Tc-nanobody was collected and counted in a 
gamma-counter (Canberra Packard). Nonspecific binding to the well was subtracted, and results were 
normalized to the TNFα-negative condition. 
 
Animal model and processing of aortas 
All animal experiments were approved by the Grenoble Research Center of the Army Health Services 
(CRSSA) committee. 35±2 (mean±SD) week-old female ApoE
-/-
 and control C57Bl/6J mice were used 
(Charles-River). ApoE
-/-
 mice (n=47) were fed a western diet containing 0.25% cholesterol (Safe) for 
18 weeks, whereas control mice (n=15) remained on a standard chow diet. 
 
Biodistribution – Each anti-VCAM1 nanobody was evaluated in 3 ApoE-/- mice except 99mTc-
cAbVCAM1-5 (n=6), which was also further evaluated in control C57Bl/6J mice (n=4). 
99m
Tc-
cAbBcII10 was evaluated as a negative control in both ApoE
-/-
 (n=4) and control mice (n=5). Two 
hours following 
99m
Tc-radiolabeled nanobody administration (67±4 MBq i.v.), SPECT/CT acquisition 
was performed (nanoSPECT, Bioscan, see below). Mice were then euthanized and aortas were cut into 
12 segments. A lesion-extension index was attributed to each segment as shown in supplemental Fig. 
1: (-) no lesion (control segments), (+) lesion covering up to 50% of the arterial segment length, (++) 
lesions covering >50% of the arterial segment length and (+++) lesions extending over the whole 
segment length. Biodistribution results were expressed as a percent of injected dose per gram of tissue 
(%ID/g). Aortic lesion and control uptakes were defined as the average uptake in all segments ranked 
(+++) or (-), respectively. Lesion-to-control, lesion-to-blood and lesion-to-heart ratios were also 
determined. Adjacent 20µm and 8µm-thick cryosections were obtained from all twelve aortic 
segments for micro-autoradiography imaging (BASS-5000, Fujifilm) and immunohistological 
VCAM1 staining, respectively. 
 6 
Competition – Biodistribution of 99mTc-cAbVCAM1-5 in ApoE-/- mice was assessed by SPECT/CT 
imaging and ex vivo by gamma-well counting with (n=6) or without (n=4) co-injecting a 100-fold 
excess of unlabeled competitor nanobody cAbVCAM1-1. Results were expressed in %ID/g. 
Pharmacodynamics – A subgroup of C57Bl/6J mice was used to evaluate 99mTc-cAbVCAM1-5 
pharmacodynamics in major organs using dynamic SPECT/CT imaging from 0 to 180 min following 
injection (86.1 ± 28.0 MBq) (n=3). Results were expressed as %ID/cm
3
. 
Blood kinetics – 99mTc-cAbVCAM1-5 blood clearance was assessed in C57Bl/6 mice (n=3) by 
collecting blood samples at several time points after injection. Results were expressed as %ID in total 
blood volume (%ID/TBV). 
 
Immunohistochemistry 
Primary anti-VCAM1 antibody (Santa-Cruz Biotechnology) was applied overnight at 4°C, 
biotinylated secondary antibody (Jackson ImmunoResearch) was incubated for 1h at 20°C and DAB 
was used as the chromogen. Staining specificity was assessed by omitting the primary antibody. In a 
subset of ApoE
-/- 
and control mice, VCAM1 immunostaining was also performed on heart, muscle, 
salivary gland, liver, bone marrow, lymph node, spleen and thymus.  
 
SPECT/CT imaging 
Two hours following i.v. injection, anesthetized animals were placed in a temperature-controlled bed 
and whole-body SPECT/CT acquisitions were performed from 2 to 3 hours p.i. (nanoSPECT, 
Bioscan). CT and SPECT acquisitions were reconstructed, fused and quantified using dedicated 
software (InVivoScope). SPECT scale was normalized to %ID/cm
3
 to allow direct visual comparison 
between animals. Regions of Interest (ROIs) were drawn at the level of the aortic arch and left 
ventricle cavity for determination of arch-to-blood ratio. 
 
Autoradiography 
For each animal, autoradiographic images were obtained following overnight exposure of 3 sets of 
20µm thick slices obtained at distinct levels of the 12 aortic segments. Images were quantified using 
dedicated software (Image Gauge, Fujifilm). ROIs were drawn around atherosclerotic lesions and 
control VCAM1-negative aortic wall. Results were corrected from background and expressed as 
average lesion-to-control ratios. 
 
Statistical analysis 
All results are presented as mean±s.e.m. Nonparametric Mann & Witney U, Wilcoxon, and Spearman 
tests were employed to compare unpaired datasets, paired datasets, and correlations between aortic 




Generation of anti-VCAM1 nanobodies 
In order to make future clinical translation possible, we aimed at developing nanobodies crossreactive 
for mouse and human VCAM1. Nanobodies were therefore generated by immunizing a dromedary 
with both mouse and human VCAM1 recombinant proteins followed by biopannings of the resulting 
phage-displayed immune nanobody library. Crude bacterial extracts containing individual nanobodies 
were screened by ELISA for binding to VCAM1 recombinant proteins and in flow cytometry to bind 
to VCAM1-expressing bEND5 cells (data not shown). 
Upon sequencing, 31 different anti-VCAM1 nanobodies were identified that could be grouped into 12 
families based on similar sequences in antigen-binding loops. Six nanobody families were mouse 
VCAM1 (mVCAM1)-specific and 6 families bound to both mouse and human VCAM1 (hVCAM1). 
Based on ELISA and flow cytometry signals of crude extracts, 10 nanobodies (called cAbVCAM1-1 
to -10) were selected for further studies. Nanobody production yield ranged from 0.8 to 10.5mg/L 
bacterial culture (Table 1). cAbBcII10, binding to a bacterial enzyme
18
, was used as a nontargeting 
control nanobody in further, comparative experiments. 
 
In vitro characterizations 
Flow cytometry analysis of mouse bEND5 and human HUVEC endothelial cells stained with an anti-
VCAM1 antibody showed low basal VCAM1 expression that was strongly elevated upon TNF-
treatment (Figure 1A-B). Under these conditions, all 10 selected nanobodies interacted with  
mVCAM1 on stimulated bEND5 cells (Figure 1A). Among them, 6 were found to be crossreactive for 
hVCAM1 expressed on stimulated HUVECs (Figure 1B). As demonstrated by SPR analyses 
summarized in Table 1 and as exemplified in Figure 1C, all selected nanobodies bound to mVCAM1 
with high affinities ranging from 0.2 to 45.7 nmol/L. Moreover, in accordance with that observed by 
flow cytometry, 6 nanobodies were found crossreactive for hVCAM1 with affinities remaining in the 
nanomolar range (Table 1). No binding to the related adhesion receptor ICAM1 was observed for any 
anti-VCAM1 nanobody, and the control nanobody cAbBcII10 did not bind to VCAM1 in SPR studies. 
Based on SPR competition studies (supplemental Figure 2), cAbVCAM1 nanobodies could be 
grouped into 3 epitope-targeting categories: cAbVCAM1-1/5, cAbVCAM1-2/3/6/7/9/10 and 
cAbVCAM1-4/8. All nanobodies exhibited high thermal stability as demonstrated by unfolding 
temperatures ranging from 59.4 to >87°C (Table 1). 
Following 
99m
Tc-radiolabeling and purification steps, radiochemical purities were >95% for all 
nanobodies. 
99m
Tc-labeling did not affect VCAM1 recognition for most binders as demonstrated by the 
in vitro binding assay on bEND5 cells (Figure 1D): besides cAbVCAM1-8, binding on VCAM1-
positive, TNFα-stimulated cells was significantly higher than on unstimulated cells. Moreover, 
binding on TNFα-stimulated cells was successfully inhibited by competition with an excess of 
unlabeled nanobody and binding of the negative control cAbBcII10 to either stimulated or untreated 
cells was negligible, thereby demonstrating specificity. 
 
Immunohistochemistry and biodistribution analyses 
As depicted in Figure 2, VCAM1 constitutive expression was observed in lymphoid tissues (i.e. bone 
marrow, lymph node, spleen and thymus) in both C57Bl/6J control and hypercholesterolemic ApoE
-/-
 
mice, whereas no VCAM1 expression was found in heart, muscle and salivary gland. VCAM1 
staining was also found in ApoE
-/-
 mice liver. Moreover, strong VCAM1 staining was also observed 
within aortic lesions at the level of the luminal endothelium, as well as inside the atherosclerotic 
plaque, but not in the aorta of control C57Bl/6J mice. 
Biodistributions of
 99m
Tc-labeled nanobodies in ApoE
-/-
 mice are summarized in supplemental Table 1. 
All nanobodies, including control cAbBcII10, exhibited high kidney uptake ranging from 97±16 to 
315±33 %ID/g and high activities in the bladder. As expected, 
99m
Tc-cAbVCAM1 uptakes in 
VCAM1-positive tissues were higher than that of the nontargeting control 
99m
Tc-cAbBcII10, a 
difference which reached statistical significance for 
99m
Tc-cAbVCAM1-3 (spleen and thymus), 
99m
Tc-
cAbVCAM1-4/5 (spleen, thymus, liver and bone marrow) and 
99m
Tc-cAbVCAM1-9 (thymus and 
liver), and 
99m
Tc-cAbVCAM1-1/8/10 (liver) (P<0.05 vs 
99m
Tc-cAbBcII10). With the exception of the 
 8 
lung (mean uptake of 2.5±0.8 %ID/g), uptake was lower than 2 %ID/g in other investigated tissues, 
including the blood and myocardium.  
Aortas from hypercholesterolemic ApoE
-/-
 mice injected with 
99m
Tc-labeled nanobodies were 
segmented and samples were macroscopically scored according to relative lesion content. As shown in 
Table 1, uptake in atherosclerotic lesions  was greater than 2 %ID/g for 6 out of 10 cAbVCAM1, with 
a maximum value of 2.99±0.07 %ID/g for 
99m
Tc-cAbVCAM1-9 (P<0.05 vs 
99m
Tc-cAbBcII10), 
whereas the lowest uptake was noted for the nontargeting control 
99m
Tc-cAbBcII10. 
Lesion-to-control, lesion-to-blood and lesion-to-heart ratios were determined from biodistribution data 
(Table 1). Lesion-to-control ratios were >2 for all VCAM1-specific nanobodies with the exception of 
99m
Tc-cAbVCAM1-8, with a maximum ratio of 4.95±0.85 for 
99m
Tc-cAbVCAM1-5 (P<0.05 vs 
99m
Tc-
cAbBcII10). Lesion-to-blood ratio was >1 for 9 out of 10 
99m
Tc-cAbVCAM1 nanobodies, with a 
maximum ratio of 5.06±0.39 for 
99m
Tc-cAbVCAM1-3 (P<0.05 vs 
99m
Tc-cAbBcII10). Finally, lesion-







Further evaluations of the lead nanobody cAbVCAM1-5 
Based on selection criteria summarized in Table 1, cAbVCAM1-5 was selected among the 10 
evaluated anti-VCAM1 nanobodies for further investigations and compared to nontargeting control 
99m
Tc-cAbBcII10. 
Stability – As demonstrated by HPLC, 99mTc-cAbVCAM1-5 was stable in vitro for up to 6 h following 
radiolabeling, as well as in vivo in the blood at 3 h post-injection, following completion of SPECT 
imaging (Figure 3A-C). 
Biodistribution.–  99mTc-cAbVCAM1-5 rapidly cleared from the circulation and background tissues 
(Supplemental Figure 3) and uptake in kidneys, bladder and VCAM1-positive lymphoid tissues was 
clearly identifiable on in vivo SPECT images from control C57Bl/6J mice, whereas only the kidneys 
and bladder were visible following the injection of the nontargeting control 
99m
Tc-cAbBcII10 (Figure 
3D and 3E). 
99m
Tc-cAbVCAM1-5 uptake in lymphoid tissues was further confirmed ex vivo by 
biodistribution analyses (Table 2). Indeed, 
99m
Tc-cAbVCAM1-5 uptake represented 7.4±0.2, 1.5±0.1 





Tc-cAbVCAM1-5 biodistribution in ApoE
-/-
 
mice major organs was similar to that observed in C57Bl/6J mice (Table 2, P=NS). 
Uptake in atherosclerotic lesions – In ApoE-/- mice, 99mTc-cAbVCAM1-5 aortic uptake correlated with 
the lesion-extension index. Indeed, 
99m
Tc-cAbVCAM1-5 uptake in individual aortic segments 
increased together with the relative volume of the atherosclerotic lesion, whereas no such gradient was 
observed for 
99m
Tc-cAbBcII10 (Sperman rho = 0.894; P<0.0001; Figure 4A). 99mTc-cAbVCAM1-5 
uptake in the aorta was further characterized using autoradiography of sections. As shown in Figure 
4B and supplemental Fig 4, 
99m
Tc-cAbVCAM1-5 accumulated within VCAM1-positive 
atherosclerotic lesions, resulting in a lesion-to-control ratio of 8.7±0.8 (P<0.05 vs cAbBcII10).  
Following SPECT/CT imaging, 
99m
Tc-cAbVCAM1-5 uptake was readily visualized on atherosclerotic 
lesions from the aortic arch of hypercholesterolemic ApoE
-/-
 mice whereas no tracer uptake was 
observed at the same location in control C57Bl/6J animals or with the nontargeting control 
99m
Tc-
cAbBcII10 in either mouse strain (Figure 5A). As a result, the 
99m
Tc-cAbVCAM1-5 aortic arch-to-
blood ratio from ApoE
-/-
 mice was significantly higher than that observed in C57Bl/6J animals or than 
that obtained following injection of the nontargeting control nanobody (P<0.05) (Figure 5B). Finally, 
coinjection with an excess of unlabeled cAbVCAM1-1, a nanobody recognizing the same VCAM1-
epitope as cAbVCAM1-5 (suppl. Fig 2B), resulted in significant decrease in 
99m
Tc-cAbVCAM1-5 
uptake in liver, lymphoid tissues and atherosclerotic lesions, thereby demonstrating specificity of the 




This study was designed to generate nanobodies recognizing both mouse and human VCAM1 
homologues since such crossreactive binders would be suitable for translation into clinical practice 
after validation in well-characterized animal models. Ten anti-mVCAM1 nanobodies, including 6 
nanobodies crossreactive with hVCAM1, were successfully generated and produced with affinities for 
mouse and/or human homologue in the nanomolar range. The elevated heat resistance of all tested 
nanobodies allowed 
99m
Tc radiolabeling at 50°C with high radiochemical purity (>95%). Furthermore, 
in vitro binding assays on VCAM1-positive mouse endothelial cells revealed that all cAbVCAM1 
remained specific mVCAM1-binders after 
99m
Tc-labeling, with the exception of cAbVCAM1-8. As 
expected due to their small size, nanobodies exhibited fast blood clearance in vivo, resulting in a mean 
circulating activity of 0.8 %ID/g at 3h p.i. in ApoE
-/-
 mice (range 0.3-1.5 %ID/g). In addition, 
myocardial background activity was also minimal (mean = 0.4 %ID/g, range 0.3-1.5). These 





. More importantly, cAbVCAM1 nanobody uptake in aortic 
atherosclerotic lesions was higher than that of a nontargeting control nanobody cAbBcII10, and this 
difference reached statistical significance for eight out of the ten evaluated nanobodies. Consequently, 
with the exception of cAbVCAM1-1, lesion-to-control, lesion-to-blood and lesion-to-heart ratios were 
all >1, with mean ratios of 3.2, 2.9 and 5.6, respectively. 
 
Uptake in VCAM1-positive tissues. In addition to the expected uptake in atherosclerotic lesions, 
most cAbVCAM1 nanobodies were taken up by lymphoid tissues in both normal and 
hypercholesterolemic mice, as demonstrated by biodistribution and in vivo SPECT imaging 
experiments. More specifically, the five cAbVCAM1 nanobodies presenting with the highest affinities 
for mVCAM1 (cAbVCAM1-2/3/4/5/9, all KD <2.5 nmol/L), exhibited the highest uptakes in the 
spleen and bone marrow. Corresponding mVCAM1 constitutive expression was observed by 
immunohistochemistry in spleen, bone marrow, lymph nodes and thymus. Therefore, cAbVCAM1 
binding to lymphoid tissues was likely due to specific VCAM1 binding in vivo. VCAM1 constitutive 









, or in human thymus
23
, bone marrow and foetal or activated 
spleen
24
. Furthermore, specific uptake of radiolabeled anti-VCAM1 antibodies in mouse lymphoid 
organs has also been demonstrated previously
25, 26
. Finally, an increase in the liver activity of several 
cAbVCAM1 nanobodies was observed, in accordance with the hepatic expression of VCAM1 that was 
evidenced in ApoE
-/-
 animals in the present study and elsewhere
27
.   
 
Selection of lead compound 
Based on the parameters summarized in Table 1, cAbVCAM1-5 was selected as the lead compound 
among 10 evaluated anti-VCAM1 nanobodies. Indeed, cAbVCAM1-5 exhibited the highest lesion-to-
control and lesion-to-heart ratios, as well as a high lesion-to-blood ratio. In addition, cAbVCAM1-5 
was crossreactive with hVCAM1 with nanomolar affinities for both mVCAM1 and hVCAM1 as 
demonstrated by SPR and flow cytometry experiments, a highly relevant result when considering the 
future potential clinical evaluation of cAbVCAM1-5. Finally, cAbVCAM1-5 also displayed the 
highest heat resistance and production yield. The absence of lysine residue in the antigen-binding 
regions was also a criterion for cAbVCAM1-5 selection, since the presence of lysine could be a 
potential hurdle for future studies requesting coupling chemistry via amino-residues, such as for 
fluorescent or radiolabeling for PET imaging. 
 
cAbVCAM1-5 in vivo imaging 
99m
Tc-cAbVCAM1-5 was stable in vitro for up to 6 h following radiolabeling as well as in vivo in 
mouse blood as demonstrated by HPLC, thereby allowing SPECT/CT imaging at 2-3h post-injection. 
At this time point, atherosclerotic lesions located within the aortic arch of ApoE
-/-
 mice were 
successfully identified by SPECT/CT imaging, with low myocardial and blood background activities. 
In vivo blocking experiments demonstrated the specificity of the uptake in VCAM1-expressing tissues. 
Autoradiography and immunohistochemistry further confirmed that 
99m
Tc-cAbVCAM1-5 aortic 
uptake was focalised in VCAM1-positive atherosclerotic lesions.
 99m
Tc-cAbVCAM1-5 is therefore a 
 10 
suitable radiotracer for the noninvasive in vivo imaging of inflammatory processes occurring in 
atherosclerotic lesions. 
 
Comparison with other radiotracers. 
Other antibody-derived radiotracers have been evaluated recently for the imaging of vulnerable 
atherosclerotic plaques using SPECT
28, 29
. However, the slow blood clearance of full-sized antibodies 
resulted in suboptimal target-to-background ratios, therefore emphasizing the need to use antibody 
fragments (Fab, scFv) or engineered variants. Among the other radiotracers previously evaluated for 
SPECT or PET imaging of atherosclerotic lesions, 
18
FDG exhibited an elevated uptake in 
macrophages, thereby allowing in vivo imaging of carotid lesions in humans
30
. However, due to high 
myocardial background, imaging of coronary lesions remains extremely challenging despite the 
potential use of a specific diet aimed at lowering myocardial uptake
31
. Similarly, in a mouse model of 
atherosclerosis, Laitinen et al. found that 
18
FDG myocardial uptake was 18.13±10.59 %ID/g in 





targeting peptide-based tracer, has recently been evaluated for PET imaging of vulnerable lesions in 
mice
15
. Interestingly and similarly to that observed in the present study, 
18
F-4V uptake was elevated in 
VCAM1-expressing tissues such as the lymph nodes and spleen, and to a lower extent in the thymus 
(3.7±0.3, 2.1±0.6 and 0.9±0.3 %ID/g at 4h p.i., respectively); however the potential specificity of this 





F-4V include a more than 40-fold higher affinity for mVCAM1 since the IC50 of 
18
F-4V was 86.6 nmol/L whereas cAbVCAM1-5 Kd was 2.0±0.0 nmol/L. Of note, 
18
F-4V affinity for 
hVCAM-1 has not been reported yet. 
99m
Tc-cAbVCAM1-5 also exhibited a lower uptake at 3h p.i. 
than 
18
F-4V at 4h p.i. in background tissues such as the blood (0.5±0.1 vs 1.5±0.4 %ID/g), 
myocardium (0.2±0.0 vs 0.6±0.2 %ID/g), and control aorta (0.6±0.1 vs 1.3±0.4 %ID/g), resulting in a 
more favorable lesion-to-control ratio in ApoE
-/-
 mice (4.95±0.85 vs 3.12).  
  
Limitations of nanobody-methodology and clinical translatability  
 
Immunization of a camelid with a target protein of interest probably remains a necessary step since 
nanobodies from naive or synthetic libraries are mostly of lower affinity. In addition, whereas the 
obtention of recombinant proteins corresponding to large extracellular domains of type I or II 
transmembrane receptors can be easily achieved, as is the case for VCAM1, the same does not hold 
for more complex structures such as heterodimeric receptors or receptors spanning the cellular 
membrane multiple times. 
When produced as recombinant proteins, evident questions arise regarding immunogenicity, toxicity 
and safety when nanobody-based tracers are designed for clinical translation. In this regards, it should 
be noted that several nanobodies, including an anti-von Willebrand Factor nanobody for prevention of 
the acute coronary syndromes, were already clinically evaluated in phase Ia, Ib, and II clinical trials 
without demonstrating adverse events and detectable immunogenicity at repeatedly administered 
therapeutic doses far above the single injected dose that will be used for diagnostic purposes as 
described in the present study
33





 for PET imaging of breast cancer patients, in which 
efficacy, safety and dosimetry will be the monitored parameters.  
 
Conclusions and perspectives 
Unlike anatomical imaging methodologies which are confronted with strong resolution requirements 
in order to distinguish distinct plaque components for the identification of vulnerable lesions based on 
the size of the necrotic core or the thickness of the fibrous cap, the challenges associated with 
atherosclerosis molecular imaging are strongly related to the sensitivity of the detection systems. 
Nuclear imaging presents an exquisite, femtomolar sensitivity which is well-suited for the molecular 
imaging of atherosclerotic lesions. This study evaluated for the first time the potential of nanobodies 
as radiotracers dedicated to nuclear cardiology. When taken into perspective with previously published 
results related to tumor imaging, our results confirm that nanobodies constitute a promising new class 
of radiotracers with great potential for noninvasive nuclear imaging. 
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In the present study, ten anti-VCAM1 nanobodies were evaluated. Procedures were carefully designed 
in order to generate nanobodies crossreactive for hVCAM1 protein. 
99m
Tc-cAbVCAM1-5 was selected 
as the most potent candidate for the development of a new radiopharmaceutical for noninvasive 
imaging of vulnerable atherosclerotic lesions. In ApoE
-/-
 atherosclerotic mice, VCAM1-positive 
lesions were successfully identified by SPECT/CT imaging using the human & mouse crossreactive 
99m
Tc-cAbVCAM1-5, thereby demonstrating a strong potential for clinical translation. 
In addition to high production yield, high stability and fast blood clearance, nanobodies engineering 
offers a number of advantages. Specifically, successful radiolabeling of nanobodies with a positron 
emitter was recently described
2







, hereby allowing the use of SPECT, PET, optical, 
ultrasound or magnetic resonance imaging systems with nanobody-based tracers. In addition, 
humanized and bivalent nanobodies can easily be generated
4, 37
. In particular, further studies will be 
conducted to evaluate the performances of bivalent cAbVCAM1 constructs targeted at two distinct 




F-labeled cAbVCAM1-5 for PET imaging of 
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cAbBcII10 0.68±0.06 1.66±0.28 1.57±0.09 4.00±0.14 ND ND 5.0 77.5±0.2 
 
Table 1. Comparison between 10 evaluated anti-VCAM1 nanobodies. Mean ± s.e.m. and rank (#) are given for parameters obtained either ex vivo by gamma-
well counting (%ID/g lesion, Lesion-to-Control ratio, Lesion-to-Blood ratio, Lesion-to-Heart ratio), or in vitro (KD for mVCAM1 or hVCAM1, Production 
yield and Tm). cAbVCAM1-5 is the most potent candidate based on these criterions. * P<0.05 vs cAbBcII10. ND, not detectable. 
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Blood 0.4±0.0 0.4±0.0 0.5±0.1 0.6±0.1 
Heart 0.1±0.0 0.2±0.0 0.2±0.0* 0.3±0.1* 
Lung 0.8±0.2 1.0±0.1 1.7±0.2* 2.3±0.3* 
Liver 1.0±0.1 0.6±0.0† 1.4±0.2 1.8±0.3* 
SM 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 
SG 0.3±0.0 0.2±0.0 0.5±0.0* 0.5±0.1* 
Thyroid 0.5±0.1 0.4±0.1 0.7±0.1 0.7±0.1 
Stomach 0.4±0.0 0.4±0.1 0.5±0.0* 0.6±0.1* 
Bile 0.5±0.1 0.4±0.1 0.3±0.0 0.7±0.2 
Kidney 350±16 267±14† 287±43 222±12 
Spleen 0.3±0.0 0.4±0.0 7.4±0.2* 9.2±1.0* 
Thymus 0.1±0.0 0.2±0.0 1.5±0.1* 1.7±0.1* 
BM 0.4±0.0 1.0±0.7 7.9±2.0* 10.7±2.9* 
 
Ex vivo biodistribution of 
99m
Tc-labeled cAbBcII10 and cAbVCAM1-5 nanobodies 3h post-injection 
in C57Bl/6J and ApoE
-/-
 mice. Results are expressed as mean ± s.e.m. * P<0.05 vs strain-matched 






Figure 1. Functionality assessment of anti-VCAM1 nanobodies. 
A and B: Flow cytometry analysis of anti-VCAM1 nanobodies on untreated VCAM1-negative (red) 
and TNFα-treated VCAM1-positive (blue) mouse bEND5 (A) or human HUVEC endothelial cells (B) 
(x: PE-A, log scale; y: %max). PE-labeled anti-VCAM1 monoclonal antibody was used as a positive 
control, whereas no nanobody and cAbBcII10 were used as negative controls. All 10 anti-VCAM1 
nanobodies bound to mouse VCAM1-positive cells (A), and 6 out of 10 nanobodies were found to be 
crossreactive for human VCAM1-positive cells (B); C: Representative sensogram of cAbVCAM1-5 
binding to mouse VCAM1. D: 
99m
Tc-nanobodies bound to VCAM1-positive, TNFα-stimulated 
bEND5 cells. 
99m
Tc-cAbVCAM1 binding to stimulated cells was significantly higher than binding to 
unstimulated cells, except for 
99m
Tc-cAbVCAM1-8. Binding was successfully blocked by an excess of 
unlabeled nanobody, thereby demonstrating specificity. * P<0.05 vs 
99m
Tc-cAbBcII10. † P<0.05 vs 





Figure 2. VCAM1 expression was observed in lymphoid tissues (i.e. bone marrow, lymph nodes, 
spleen and thymus) of both C57Bl/6J control and hypercholesterolemic ApoE
-/-
 mice via 
immunohistochemistry, whereas no VCAM1 expression was found in heart, muscle and salivary 
glands. VCAM1 expression was also found in ApoE
-/-
 mice liver. Furthermore, strong VCAM1 
expression was observed within aortic lesions, at the level of the endothelium, as well as inside the 
atherosclerotic plaque. The specificity of these results was demonstrated by the absence of staining on 







Tc-cAbVCAM1-5 HPLC profiles indicating that this nanobody was stable in vitro at 0 (A) and 6 
hours (B) following radiolabeling, as well as in vivo in the blood 3 hours post-injection (C). 
Representative in vivo SPECT/CT whole body maximum intensity projections images (MIP) of 
control 
99m
Tc-cAbBcII10 (D) and 
99m
Tc-cAbVCAM1-5 (E) nanobodies obtained 2-3h following i.v. 
injection in C57Bl/6J mice. 
99m
Tc-cAbVCAM1-5 was taken up at the level of the bladder (Bl) and 
kidneys (Kd) as well as in the lymphoid tissues : lymph nodes (LN), bone marrow (BM), thymus (Tm) 












cAbBcII10 aortic uptake in arterial segments from ApoE
-/-
 mice ranked according to the lesion-
extension index, and in C57Bl/6J control mice aorta. * P<0.05 vs C57Bl/6J, 
†
 P<0.05 vs next lesion-




Tc-cAbBcII10 autoradiograms (ARG) 
are presented together with VCAM1 immunostainings obtained on adjacent slices, showing hot-spot 
uptake of 
99m







Tc-cAbVCAM1-5 as tracer for SPECT/CT in vivo imaging of atherosclerotic plaques.  A: 
Representative in vivo SPECT/CT coronal views taken at the level of the aortic arch of C57Bl/6J and 
ApoE
-/-




Tc-cAbVCAM1-5 nanobodies. The 
scale was adjusted from 1 to 3.4 percent of the injected dose to allow direct visual comparison. Focal 
uptake of 
99m
Tc-cAbVCAM1-5 was visible in the axillary lymph nodes (ln) and thymus (t) of both 
C57Bl/6J and ApoE
-/-
 mice. In addition, 
99m
Tc-cAbVCAM1-5 uptake in atherosclerotic lesions from 
ApoE
-/-
 mice was also clearly identifiable at the level of the aortic arch (ao). B: In vivo determination 
of arch-to-blood ratios based on SPECT image quantifications. This ratio was significantly higher in 
atherosclerotic ApoE
-/-
 than control C57Bl/6J mice for 
99m
Tc-cAbVCAM1-5 but not for the negative 
control 
99m
Tc-cAbBcII10. (* P<0.05 vs 
99m
Tc-cAbBcII10, † P<0.05 vs C57BL/6J). 
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Figure 6. In vivo competition study. 
99m
Tc-cAbVCAM1-5 was injected in ApoE
-/-
 mice either alone (n=4), or together with a 100-fold 
excess of unlabeled competitor cAbVCAM1-1 (n=6). A: Representative SPECT/CT images. B: ex vivo 
biodistribution at 3h p.i. Competition resulted in significant decreases of 
99m
Tc-cAbVCAM1-5 uptake 
in liver, lymphoid tissues and atherosclerotic lesions, thereby demonstrating specificity of the signals. 
* : P<0.05 vs no competition. 
 
